Study finds three-month TB treatment regimen just as effective as standard longer course

"Health officials on Monday celebrated a faster treatment for people who have tuberculosis but aren't infectious, after investigators found a new combination of pills knocks out the disease in three months instead of nine," the Associated Press/Seattle Times reports (Stobbe, 5/16).

According to a study, which was presented at a medical meeting on Monday, patients with latent TB "who took a combination of two drugs just 12 times over three months fared as well as those who received the standard treatment that requires 270 daily doses," Reuters reports (Berkrot, 5/17). "In the study, begun 10 years ago, researchers enrolled 8,053 people with latent TB, most living in the U.S. and Canada, though some were in Brazil and Spain. Half were selected to receive conventional daily isoniazid treatment for nine months and half received a combination of isoniazid and rifapentine weekly for 12 weeks," the Los Angeles Times notes. "In the 33 months of follow-up, seven of those receiving the combination therapy developed TB, compared with 15 of those receiving isoniazid alone, coauthor Dr. Timothy Sterling of Vanderbilt University reported at the American Thoracic Society International Conference in Denver," according to the newspaper (Maugh, 5/17).

"New, simpler ways to prevent TB disease are urgently needed, and this breakthrough represents one of the biggest developments in TB treatment in decades," CDC Director Thomas Frieden said in a statement, Reuters reports. CDC sponsored the study (5/17). According to a CDC press release, "Additional studies will likely be needed before this new regimen can be recommended in countries with a high incidence of TB, especially those with high HIV prevalence and where the risk of TB re-infection is greater," because of interactions between some HIV medications and rifapentine (5/16).

http://www.kaiserhealthnews.orgThis article was reprinted from with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Elite Controllers: Do their genomes hold the key to curing HIV?